Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, June 30, 2021
Alfresa Holdings Corporation

Notice Regarding a Judgment on a Violation of the Antimonopoly Act

Today, a consolidated subsidiary, Alfresa Corporation (head office: Chiyoda-ku, Tokyo; hereafter "Alfresa"), received a judgment to pay a fine of JPY 250 million by the Tokyo District Court. Alfresa was prosecuted on December 9, 2020, by the Tokyo District Public Prosecutors Office for violating the Antimonopoly Act in relation to bits for supplying ethical pharmaceuticals to the Japan Community Health care Organization (JCHO). The employees prosecuted together with Alfresa also received imprisonment with a suspended sentence today.

We sincerely apologize for the great inconvenience and concern to our shareholders, customers, business partners, and all other stakeholders.

The Company and Alfresa take it seriously that we have reached such a situation. As reported in the release on December 14, 2020, we will continue to work tirelessly to reinforce our compliance and push forward with Alfresa Group's Recurrence Prevention Measures as well as do its utmost to restore the trust of stakeholders as soon as possible.

About Alfresa Group

The Alfresa Group is a leader in Japanese healthcare industry, which is dedicated to make its corporate philosophy "we create and deliver a fresh life for all" come true through a wide range of business lines, including ethical pharmaceutical wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE: 2784) reported its consolidated revenue of JPY 2.6 trillion (USD 24 billion) for the fiscal year ended March 31, 2021. For more information, please see:
https://www.alfresa.com/eng/